A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Prochymal (ex vivo cultured adult human mesenchymal stem cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Grants and Contracts Details

StatusFinished
Effective start/end date10/1/08 → 9/30/12

Funding

  • Osiris Therapeutics Inc: $31,287.00